Charles Schwab’s Forte Biosciences FBRX Stock Holding History

Charles Schwab’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-992	Closed	-$37K	–	3571
2022 Q1	$37K	Hold	992	–	–	﹤0.01%	3559
2021 Q4	$54K	Sell	992 -143	-13%	-$9.62K	﹤0.01%	3506
2021 Q3	$84K	Buy	1,135 +35	+3%	+$19.4K	﹤0.01%	3395
2021 Q2	$925K	Buy	+1,100	New	+$991K	﹤0.01%	2960
2020 Q2	–	Sell	-136	Closed	-$63K	–	3333
2020 Q1	$63K	Hold	136	–	–	﹤0.01%	3141
2019 Q4	$28K	Hold	136	–	–	﹤0.01%	3148
2019 Q3	$34K	Hold	136	–	–	﹤0.01%	3138
2019 Q2	$341K	Buy	136 +10	+8%	+$29.7K	﹤0.01%	2974
2019 Q1	$513K	Buy	126 +23	+22%	+$88.9K	﹤0.01%	2761
2018 Q4	$318K	Hold	103	–	–	﹤0.01%	2917
2018 Q3	$604K	Buy	103 +23	+29%	+$87.6K	﹤0.01%	2773
2018 Q2	$280K	Hold	80	–	–	﹤0.01%	2999
2018 Q1	$355K	Hold	80	–	–	﹤0.01%	2828
2017 Q4	$307K	Buy	80 +43	+116%	+$172K	﹤0.01%	2869
2017 Q3	$171K	Hold	37	–	–	﹤0.01%	3031
2017 Q2	$165K	Buy	+37	New	+$208K	﹤0.01%	3057

Other funds holding FBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Charles Schwab's FBRX Position: Q2 2022 in Review

Charles Schwab sold out of Forte Biosciences (FBRX) in Q2 2022, closing a stake of 992 shares — an estimated $37K sold.

Charles Schwab first reported a position in FBRX in Q2 2017 and held it in 16 quarters. The position peaked at $925K in Q2 2021. 39 funds tracked by Wall St. Rank hold FBRX as of Q2 2022.

Charles Schwab reported no remaining Forte Biosciences position as of Q2 2022 after selling out during the quarter.
Charles Schwab sold 992 Forte Biosciences shares in Q2 2022, an estimated $37K.
Charles Schwab first reported a position in Forte Biosciences in Q2 2017 and held it in 16 quarters.
Charles Schwab's Forte Biosciences position peaked at $925K in Q2 2021.
39 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.